



# PHARMA MONTHLY

SEPTEMBER 2022

**PROGRESSIVE**<sup>®</sup>  
Your Progress Our Priority...

Equities | Derivatives | Commodities | Currency | Depository | Mutual Funds | NBFC | e-Broking



## Key News for the Month

### Company

- USFDA issues 11 observations each for two sites in Bengaluru: Biocon
- Aurobindo Pharma's arm to invest around Rs300cr for capacity expansion
- GSK's pharma brands doing well: India MD
- Cipla, JB Chemicals, Torrent lead Rs 4,500-crore race for Medley Pharma
- Lupin and DKSH sign an exclusive licensing and supply agreement to market five biosimilar candidates in the Philippines
- Zydus announces positive Phase 2 Proof-of-Concept of NLRP3 inhibitor, ZYL1 in patients with Cryopyrin Associated Periodic Syndrome (CAPS)
- Dr. Reddy's Laboratories announces the launch of lenalidomide capsules in the US with two of six strengths eligible for first-to-market, 180- day exclusivity
- Dr. Reddy's launches generic Revlimid in US market
- Lupin launches generic Suprep Bowel Prep Kit in the US
- IOL to diversify its API and specialty chemicals portfolios to boost sales
- Zydus in-licenses a critical drug for CKD patients from Pharmacosmos A/S of Denmark
- Bharat Biotech seeks DCGI nod for phase-3 study of intranasal Covid vaccine in 5-18 age group
- Ajanta Pharma's Dahej facility received Form 483 with 2 procedural observations
- Alkem Laboratories gets Form 483 approval from USFDA
- Glenmark bets on respiratory drug, licensing deals to improve business
- Natco gets CTPR launch approval from Delhi High Court
- Glenmark Pharma's Baddi facility receives OAI from the USFDA
- Cipla received an EIR for its Indore plant
- Bausch Health, Glenmark announce approval of Ryaltris in Canada
- Hester Biosciences meets demand for Goat Pox vaccine in India
- Torrent Pharma to acquire Sequoia-backed Curatio Health for Rs2,000cr
- USFDA issues warning letter to Lupin's Tarapur unit
- DCGI allows Serum Institute to export malaria vaccine to UK

### Industry

- Indian pharma market grew 12.1% in August, AWACS report
- Several antibiotics, other drugs may get cheaper
- Indian pharma seeks greater access to USD58bn South American markets
- Pharma industry staring at 30-40bps hit on updated NLEM

### Global

- FDA grants Breakthrough Therapy Designation to Pfizer's Group B Streptococcus vaccine candidate
- Novartis announces tislelizumab efficacy results from phase 3 trial
- WHO grants prequalification to GSK's Mosquirix - the first and only approved malaria vaccine
- Pfizer to supply global fund up to 6 million Paxlovid treatment courses for low-and-middle-income countries

## Tentative ANDA Approvals

Company	API	Strengths	Indications	Brand (Company)	Mkt Size
<b>Zydus Lifesciences</b>	Sugammadex Injection	200mg/2mL (100mg/mL) and 500mg/5mL (100mg/mL), Single-Dose Vial	Reversal of neuromuscular blockade	Bridion (Merck Sharp & Dohme Corp)	USD772mn
<b>Shilpa Medicare</b>	Tenofovir Alafenamide Tablets	25mg	Treatment of chronic hepatitis B virus	Vemlidy tablets, (Gilead Sciences Inc.)	USD498.14mn

Source: Media Reports and Company Press Releases

## Final ANDA Approvals

Company	API	Strengths	Indications	Brand (Company)	Mkt Size
<b>Zydus Lifesciences</b>	Cariprazine Capsule	1.5/3/4.5/6mg	Indicated for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder	VRAYLAR (Allergan)	USD2.39bn (annual sales July 2022)
<b>Lupin</b>	Diclofenac Sodium Topical Solution	2% w/w	Used to treat pain in the knees caused by osteoarthritis	Pennsaid (Horizon Pharma Ireland DAC)	USD484mn (annual sales June 2022)

Source: Media Reports and Company Press Releases

BSE Health Care Index Price Performance				
Companies	Price	Change		
		1 M	6 M	12 M
Aarti Drugs Ltd	468	8.4%	10.3%	-23.0%
Abbott India Ltd	19122	2.0%	10.8%	-6.9%
Ajanta Pharma Ltd	1260	-8.0%	2.1%	-17.2%
Albert David Ltd	576	5.9%	6.4%	-3.7%
Alembic Ltd	67	-8.4%	-9.2%	-41.5%
Alkem Laboratories Ltd	3280	10.2%	-10.8%	-17.6%
Ami Organics Ltd	913	-7.9%	-6.4%	-28.6%
Anuh Pharma Ltd	91	-0.3%	5.4%	-20.8%
Alembic Pharmaceuticals Ltd	604	-6.8%	-19.8%	-23.4%
Apollo Hospitals Enterprise Ltd	4383	1.5%	-4.8%	-2.3%
Aster DM Healthcare Ltd	253	14.4%	29.0%	18.1%
AstraZeneca Pharma India	3108	1.3%	20.0%	0.6%
Aurobindo Pharma Ltd	511	-6.4%	-24.4%	-29.7%
Bajaj Healthcare Ltd	354	-1.3%	2.0%	-19.7%
Biocon Ltd	291	-6.1%	-14.8%	-19.8%
Bliss GVS Pharma Ltd	76	-1.9%	8.9%	-30.5%
Caplin Point Laboratories Ltd	745	-4.2%	8.46%	-15.8%
Cipla Ltd/India	1115	7.3%	8.1%	13.3%
Dishman Carbogen Amics Ltd	97	-17.4%	-48.9%	-51.4%
Divi's Laboratories Ltd	3685	1.6%	-18.8%	-23.2%
Dr. Reddy's Laboratories Ltd	4334	2.1%	-0.4%	-11.3%
Eris Lifesciences Ltd	703	2.0%	2.2%	-7.6%
FDC Ltd	264	0.4%	2.4%	-24.3%
Fermenta Biotech Ltd	207	14.9%	-0.1%	-23.4%
Fortis Healthcare Ltd	264	-10.3%	-5.9%	0.2%
Gland Pharma Ltd	2095	-11.0%	-35.2%	-43.8%
GSK Pharmaceuticals Ltd	1424	-2.4%	-13.6%	-3.8%
Glenmark Pharmaceuticals Ltd	389	4.7%	-13.6%	-23.9%
Glenmark Lifesciences Ltd	385	-12.4%	-19.1%	-43.3%
Granules India Ltd	345	12.8%	11.4%	7.8%
Gufic Biosciences Ltd	217	2.6%	-13.1%	11.9%
Gujarat Themis Biosyn Ltd	634	22.3%	48.7%	3.1%
HealthCare Global Enterprises Ltd	287	4.9%	5.8%	16.3%
Hester Biosciences Ltd	2020	-4.5%	-23.2%	-18.8%
Hikal Ltd	336	-2.0%	-16.8%	-44.3%
Indoco Remedies Ltd	327	-9.0%	-14.0%	-27.1%
Indraprastha Medical Corp. Ltd	63	-9.4%	6.6%	-19.6%
IND-Swift Laboratories Ltd	56	-7.0%	-9.3%	-13.5%
IOL Chemicals and Pharma Ltd	350	-3.2%	-3.8%	-41.1%
IPCA Laboratories Ltd	916	1.1%	-14.9%	-24.0%
J.B.Chemicals & Pharmaceuticals Ltd	1917	8.1%	22.3%	2.8%
Jubilant Life Sciences Ltd	336	-4.3%	-15.9%	-46.2%
KIMS Ltd	1507	25.4%	7.7%	23.6%
Kopran Ltd	158	-15.0%	-44.0%	-21.0%
Kovai Medical Center & Hospital Ltd	1512	1.4%	-6.2%	-10.6%
Krsnaa Diagnostics Ltd	500	4.0%	0.1%	-35.1%
Lal PathLabs Ltd	2521	-1.8%	-3.8%	-31.5%
Lasa Supergenerics Ltd	37	4.9%	-9.1%	-51.7%


Source: BSE website; All prices are as on 30th Sept, 2022

BSE Health Care Index Price Performance				
Companies	Price	Change		
		1 M	6 M	12 M
Laurus Labs Ltd	513	-11.4%	-14.3%	-16.9%
Lincoln Pharmaceuticals Ltd	285	-1.2%	-9.1%	-30.9%
Lupin Ltd	680	1.6%	-9.3%	-28.5%
Marksans Pharma Ltd	47	-10.8%	0.4%	-32.5%
Max Healthcare Institute Ltd	410	6.6%	13.5%	13.9%
Medicamen Biotech Ltd	1026	-12.6%	59.0%	76.6%
Metropolis Healthcare Ltd	1560	8.7%	-23.7%	-42.2%
Morepen Laboratories Ltd	24	-30.6%	-36.6%	-57.8%
Natco Pharma Ltd	606	-1.6%	-21.4%	-32.0%
Nectar Lifesciences Ltd	21	-8.3%	-14.5%	-28.7%
Neuland Laboratories Ltd	1363	7.4%	35.4%	-12.2%
NGL Fine-Chem Ltd	1481	-7.0%	-21.6%	-47.0%
Narayana Hrudayalaya Ltd	720	2.7%	-1.0%	43.4%
Novartis India Ltd	680	-6.9%	14.2%	-16.8%
Nureca Ltd	899	-10.0%	-35.2%	-44.2%
Panacea Biotech Ltd	131	-4.1%	-15.6%	-54.0%
Pfizer Ltd (India)	4262	1.9%	-2.6%	-23.6%
Procter & Gamble Health Ltd	4090	-2.8%	1.9%	-24.5%
Poly Medicure Ltd	865	1.5%	-6.0%	-6.7%
RPG Life Sciences Ltd	808	11.5%	44.1%	17.7%
Sanofi India Ltd	5788	-6.5%	-22.8%	-25.8%
Sastasundar Ventures Ltd	315	-9.9%	-10.7%	9.3%
Sequent Scientific Ltd	103	-8.9%	-24.5%	-52.9%
Shalby Ltd	130	2.6%	9.1%	-25.9%
Shilpa Medicare Ltd	386	-1.8%	-4.4%	-30.6%
Sigachi Industries Ltd	269	-7.7%	-8.8%	-
SMS Pharmaceuticals Ltd	88	8.2%	-9.0%	-43.5%
Solara Active Pharma Sciences Ltd	417	-7.7%	-39.7%	-74.0%
SPARC Ltd	220	-4.5%	-26.7%	-25.7%
Strides Pharma Science Ltd	333	0.5%	-6.6%	-43.5%
Sun Pharmaceutical Industries Ltd	949	6.2%	3.1%	16.0%
Supriya Lifescience Ltd	302	-14.8%	-39.4%	-
Suven Life Sciences Ltd	71	-2.8%	-14.3%	-24.0%
Suven Pharmaceuticals Ltd	454	-7.3%	-25.1%	-15.0%
Snycom Formulations (India) Ltd	8	-6.8%	-25.2%	15.7%
Syngene International Ltd	561	-6.6%	-6.3%	-6.4%
Take Solutions Ltd	24	-6.4%	-16.3%	-52.5%
Tarsons Products Ltd	810	5.4%	19.8%	-
Thyrocare Technologies Ltd	700	13.0%	87.3%	-40.0%
Torrent Pharmaceuticals Ltd	1559	0.4%	10.5%	1.3%
TTK Healthcare Ltd	940	9.3%	14.7%	39.3%
Unichem Laboratories Ltd	388	26.5%	50.8%	43.0%
Venus Remedies Ltd	206	-5.6%	-21.5%	-54.3%
Vijaya Diagnostic Centre Ltd	462	29.7%	5.0%	-
Vimta Labs Ltd	340	-9.2%	4.6%	21.3%
Windlas Biotech Ltd	235	4.9%	9.7%	-35.1%
Wockhardt Ltd	244	1.2%	-11.4%	-46.4%
Zydus Lifesciences Ltd	387	2.3%	8.7%	-29.9%

Source: BSE website; All prices are as on 30th Sept, 2022

NIFTY PHARMA COMPANIES					
Company	Price (Rs)	Mcap (Rs mn)	Change		
			1 M	6 M	12 M
Abbott India Ltd	19122	406319	2.0%	10.8%	-6.9%
Alkem Laboratories Ltd	3280	392143	10.2%	-10.8%	-17.6%
Alembic Pharmaceuticals Ltd	604	118783	-6.8%	-19.8%	-23.4%
Aurobindo Pharma Ltd	511	299122	-6.4%	-24.4%	-29.7%
Biocon Ltd	291	349195	-6.1%	-14.8%	-19.8%
Cipla Ltd	1115	894590	7.3%	8.1%	13.3%
Divi's Laboratories Ltd	3685	978119	1.6%	-18.8%	-23.2%
Dr. Reddy's Laboratories Ltd	4334	646564	2.1%	-0.4%	-11.3%
Gland Pharma Ltd	2095	345004	-11.0%	-35.2%	-43.8%
Glenmark Pharmaceuticals Ltd	389	109651	4.7%	-13.6%	-23.9%
Granules India Ltd	345	85624	12.8%	11.4%	7.8%
Ipca Laboratories Ltd	916	232266	1.1%	-14.9%	-24.0%
Laurus Labs Ltd	513	275397	-11.4%	-14.3%	-16.9%
Lupin Ltd	680	308962	1.6%	-9.3%	-28.5%
Natco Pharma Ltd	606	110584	-1.6%	-21.4%	-32.0%
Pfizer Ltd	4262	194954	1.9%	-2.6%	-23.6%
Strides Pharma Science Ltd	333	29878	0.5%	-6.6%	-43.5%
Sun Pharmaceutical Industries Ltd	949	2276969	6.2%	3.1%	16.0%
Torrent Pharmaceuticals Ltd	1559	527518	0.4%	10.5%	1.3%
Zydus Lifesciences Ltd	387	395881	2.3%	8.7%	-29.9%

Source: NSE website, Company Research; All prices are as on 30th Sept, 2022



Source: NSE website

#### DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

#### Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

#### Registered Office Address:

Progressive Share Brokers Pvt. Ltd,  
122-124, Laxmi Plaza, Laxmi Indl Estate,  
New Link Rd, Andheri West,  
Mumbai—400053, Maharashtra  
www.progressiveshares.com | Contact No.:022-40777500.

#### Compliance Officer:

Mr. Shyam Agrawal,  
Email: compliance@progressiveshares.com,  
Contact No.:022-40777500.